一品红(300723.SZ)：子公司获得盐酸克林霉素棕榈酸酯颗粒注册证书

Core Viewpoint - Yipinhong (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has received the drug registration certificate for Clindamycin Palmitate Hydrochloride Granules from the National Medical Products Administration [1] Group 1: Product Approval - The drug is indicated for severe infections caused by sensitive anaerobic bacteria [1] - Clindamycin is also suitable for severe infections caused by sensitive strains such as Streptococcus, Pneumococcus, and Staphylococcus, specifically for patients allergic to penicillin or deemed unsuitable for penicillin use by a physician [1] - The approved instructions include specific dosage and administration guidelines for children [1] Group 2: Mechanism of Action - Clindamycin works by inhibiting bacterial protein synthesis through binding to the 23S rRNA of the 50S ribosomal subunit [1]